View More
Dr Yara Abdou discusses BRCA mutation testing and adjuvant therapy with olaparib in BRCA-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)
Yara Abdou, MD
Physicians:
maximum of 0.75 AMA PRA Category 1 Credits™
Registered Nurses:
0.75 Nursing contact hours
Pharmacists:
0.75 contact hours (0.075 CEUs)
Released: May 17, 2022
Expired:
May 16, 2023
Slideset from Dr Yara Abdou on adjuvant olaparib in BRCA1/2-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)
Yara Abdou, MD
Released: May 17, 2022
Dr. Yara Abdou discusses Ki-67 testing and adjuvant abemaciclib in HR+/HER2-, node-positive, high-risk early breast cancer, from Clinical Care Options (CCO)
Yara Abdou, MD
Physicians:
maximum of 0.5 AMA PRA Category 1 Credits™
Registered Nurses:
0.5 Nursing contact hours
Pharmacists:
0.5 contact hours (0.05 CEUs)
Released: May 12, 2022
Expired:
May 11, 2023
Slideset from Dr. Yara Abdou on Ki-67 and adjuvant abemaciclib for HR+/HER2-, node-positive, high-risk EBC, from Clinical Care Options (CCO)
Yara Abdou, MD
Released: May 12, 2022
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.